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Abstract: Angiogenesis, the process of formation of new blood vessel from pre-existing 
ones, is involved in various intertwined pathological processes including virus infection, 
inflammation and oncogenesis, making it a promising target for the development of novel 
strategies for various interventions. To induce angiogenesis, angiogenic growth factors (AGFs) 
must interact with pro-angiogenic receptors to induce proliferation, protease production 
and migration of endothelial cells (ECs). The action of AGFs is counteracted by antiangiogenic 
modulators whose main mechanism of action is to bind (thus sequestering or masking) 
AGFs or their receptors. Many sugars, either free or associated to proteins, are involved  
in these interactions, thus exerting a tight regulation of the neovascularization process. 
Heparin and heparan sulfate proteoglycans undoubtedly play a pivotal role in this context 
since they bind to almost all the known AGFs, to several pro-angiogenic receptors and 
even to angiogenic inhibitors, originating an intricate network of interaction, the so called 
“angiogenesis glycomic interactome”. The decoding of the angiogenesis glycomic interactome, 
achievable by a systematic study of the interactions occurring among angiogenic modulators 
and sugars, may help to design novel antiangiogenic therapies with implications in the cure 
of angiogenesis-dependent diseases. 
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1. The Process of Neovascularization 
Angiogenesis is the process of formation of new blood vessel from pre-existing ones. It plays key 
roles in embryonic development, inflammation and wound repair. Moreover, it is involved in several 
pathologies, among which tumor growth and metastasization [1]. In effect, the local, uncontrolled release 
of angiogenic growth factors (AGFs) and/or alterations of the production of natural angiogenic inhibitors, 
with a consequent alteration of the angiogenic balance [2], are responsible for the uncontrolled 
neovascularization that takes place during tumor growth [3]. 
Angiogenesis is a multi-step process that leads endothelial cells (ECs) stimulated by AGFs to 
acquire the so called “angiogenic phenotype”. It begins with the release of effectors (i.e., proteases 
urokinase-type plasminogen activator and matrix metalloproteinases), that degrade the extracellular 
matrix (ECM) creating a permissive environment for the migration and proliferation of activated EC 
that in this way originate solid sprouts into the stromal space, a process regulated by lateral cell-cell 
adhesion and ECM interactions mediated by a tightly time-regulated expression of cadherins, integrins 
and ECM components [4–6]. Lately, ECs present in the sprouts undergo “morphogenesis”, consisting 
in their organization in “capillary-like structures” that will mature in functional vessels, a process that 
still requires the proteolytic machinery [7], integrins [4] and junctional adhesion molecules [5] that, 
again, are controlled by the activity of AGFs and their tyrosine kinase receptors (TKRs) [8] (Figure 1). 
 
Figure 1. The process of tumor angiogenesis: AGFs released by tumor cells originate  
a chemotactic gradient that, reaching the ECs of a pre-existing vessel, stimulates an array 
of biological activities and phenotypical changes collectively known as “angiogenic 
phenotype” that lead to solid sprouts protruding from the original vessel. Then, AGFs and 
newly deposed ECM components orchestrate vascular morphogenesis by which sprouting 
ECs organize into tubes with functional lumens. 
The vascular endothelial growth factors (VEGFs) family comprises six subgroups of proteins: 
VEGF-A, B, C, D and E and placental growth factor (PlGF), with VEGF-A representing the  
most important member involved in angiogenesis. Through alternate mRNA splicing, the VEGF-A 
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gene codifies for various isoforms that differ by the presence or absence of a short C-terminal  
heparin-binding domain. VEGFs differently interact with three distinct TKRs (VEGFRs) expressed on 
ECs, among which VEGFR2 (KDR) seems to be the primary pro-angiogenic receptor. It derives  
that the VEGF-A/VEGFR2 system represents by far the most studied target for the development of 
antiangiogenic drugs. However, to induce a full angiogenic response in ECs, VEGF-A also needs to 
interact and activate integrin αvβ3 [9], neurophilin-1 (NRP-1) [10] and heparan sulfate proteoglycans 
(HSPGs) (discussed below). 
Up to 22 members of the fibroblast growth factor (FGF) family have been identified, many of which 
endowed with angiogenic activity [11]. Prototypic FGF2 is a pleiotropic factor that, in addition to ECs, 
also acts on other cell types by interacting with a family of four TKRs named FGFRs [12]. Prototypic 
FGFR1 is widely expressed on ECs and its interaction with FGF2 triggers the activation of complex 
pro-angiogenic program [13]. However, to induce a full angiogenic response, FGF2 also needs to 
interact with integrin αvβ3 [14], ganglioside GM1 [15], NRP-1 [16] and HSPGs (discussed below). 
Beside VEGFs and FGFs, many other canonical and non-canonical AGFs induce neovascularization 
(see Section 3.1). These AGFs can act either directly, by inducing EC to acquire the angiogenic 
phenotype (as typically done by VEGF-A or FGF-2) or indirectly, by inducing the production of AGFs 
by ECs or by other cells [as done by high mobility group box 1 (HMGB1) [17], fibronectin (FN) [18], 
heparanase [19] and activated blood coagulation factor X (FXa) [20]]. 
A tight correlation exists between angiogenesis and inflammation [1] during which macrophages 
produce AGFs and cytokines endowed with direct or indirect angiogenic capability [21]. Accordingly, 
VEGF-A synergizes with tumor necrosis factor (TNF)-α [22] and CXCL8 [23], while CCL2 synergizes 
with both VEGF-A [24] and FGF2 [25] in inducing angiogenesis. A tight correlation also exists 
between angiogenesis and viral infection [26], with some viral proteins released by infected cells  
that exert an angiogenic activity. In effect, during HIV infection, the transactivating factor Tat can 
synergize with both VEGF-A [27] and FGF2 [28] to induce neovascularization. It derives that, in  
a given physiopathological setting, neovascularization is almost always the result of the simultaneous 
actions of different AGFs, as also demonstrated in advanced stages of human tumors, characterized by 
a marked vascularization and the simultaneous expression of different AGFs at high levels [29,30].  
These considerations had a deep impact in the field of antiangiogenic drug discovery. In effect, the 
possibility to inhibit neovascularization in vivo by using inhibitors selectively directed against a single 
AGF is unlikely, as sustained by the observation that the numerous antiangiogenic drugs so far developed 
turned out to be of little therapeutical benefit in clinical trials [31]. This failure calls for more  
wide-ranging studies functional to the identification of common biochemical/biological themes shared 
by different AGFs to be exploited in the design of multitarget drugs able to inhibit simultaneously 
different AGFs (see Section 5).  
Natural antiangiogenic compounds are a heterogeneous group of proteins, polysaccharides and 
glycosphingolipids present in body fluids and ECM whose common theme is the ability to bind and 
sequester AGFs hampering their interaction with ECs [6]. Alternatively, some of them can act directly 
on ECs inducing their apoptosis or a decrease of their responsiveness to AGFs. 
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2. Heparin and HSPGs 
Heparin and/or HSPGs bind to almost all the AGFs, to some pro-angiogenic receptors and even to 
some angiogenesis effectors, exerting modulations that can be even opposite and emerging as preferential 
target (or template) for the development of novel multitarget antiangiogenic drugs. 
Glycosaminoglycans (GAGs) are unbranched anionic polysaccharides (Figure 2) found as free 
molecules (such as heparin) or as proteoglycans composed of one or more GAG chains attached to  
a core protein. Heparin is synthesized by mast cells as a proteoglycan with very high molecular weight 
GAG chains that are then depolymerized by endoglycosidases to obtain the final product. HSPGs are 
instead present in almost all the cell types segregated into intracellular granules, associated with the 
plasma membrane or to the ECM and even in soluble forms after their mobilization [32]. 
The biosynthesis of heparin/heparan sulfate (HS) consists of three phases: addition of the linkage 
region to the core protein, chain elongation and chain modifications [33]. All the modifications are 
incomplete in vivo, so that not all the sugar residues are effectively modified. Also, since 2-O- and  
6-O-sulfation occur only after C5 epimerization (that in turn needs the previous N-deacetylation/N-sulfation 
reaction) the distribution of 2-O- and 6-O-sulfate groups is restricted to N-sulfate regions. The partial 
modification of GAGs is the basis for their structural heterogeneity (i.e., different chain length or the 
amount and distribution of sulfate groups). 
In heparin, the modification process is more complete than in HS, so that its structure is more 
homogeneously composed by regular trisulfated disaccharide sequences made up of alternating,  
α-1,4-linked residues of IdoA2S and N,6-disulfate D-glucosamine (GlcNS6S) (Figure 2). These regular 
sequences are occasionally interrupted by nonsulfated uronic acids [either glucuronic (GlcA)  
or iduronic acid (IdoA)] and by undersulfated hexosamines (GlcNS, GlcNAc, GlcNAc6S). The less 
extensive modifications that occur during the biosynthesis of HS lead to GAG chains characterized by 
low IdoA content, low overall degree of O-sulfation and a heterogeneous distribution of the sulfate 
groups. Eventually, disaccharides containing GlcNAc or GlcNS may form clusters ranging from 2 to 
20 adjacent GlcNAc-containing disaccharides and 2–10 adjacent GlcNS-containing disaccharides. 
However, about 20%–30% of the chains contains alternate GlcNAc and GlcNS disaccharides units [34]. 
HSPGs are found associated to the surface of almost all eukaryotic cells, including ECs,  
at concentrations ranging between 105–106 molecules/cell. HSPGs can link to the plasma  
membrane through a hydrophobic transmembrane domain of their core protein or through  
a glycosyl-phosphatidylinositol (GPI) covalently bound to the core protein [33]. Transmembrane 
HSPGs are the syndecans, the most represented HSPGs on ECs [33] characterized by a core protein 
composed of a heavily glycosilated extracellular domain, a trans-membrane domain and a cytoplasmic 
domain that interact with the cytoskeleton and contains sequences for tyrosine phosphorylation, 
enabling them to transduce a signal in the cell [33] (Figure 2). Glypicans are instead GPI-anchored 
HSPGs, while perlecan is the most represented HSPG in endothelial ECM [35] and can be also  
found tethered to integrins of the EC surface [36] (Figure 2). HSPGs also exist also in soluble form 
following their mobilization from the cell-surface. Transmembrane HSPGs are released after 
proteolytic digestion of their core protein, GPI-anchored HSPGs are instead released by endogenous 
phospholipase [37] (Figure 2). 
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Figure 2. Schematic representation of the main HSPGs species syndecans, glypicans and 
perlecan and of their GAG chains. R = H, SO3Na. See text for further details. 
The biological functions of heparin/HSPGs range from simple mechanical support functions to 
more articulate effects on cell proliferation and differentiation. These effects are mainly due to  
the ability of HSPGs to act as “receptors” for adhesion molecules, cytokines, proteases, coagulation 
enzymes and AGFs. HSPGs associated to the basal site of the endothelium act as receptors for basement 
membrane proteins, while those at the luminal surface contribute to the anticoagulative properties of 
the vessel surface [38] and to the internalization of lipoprotein lipase [39]. The expression of HSPGs 
on ECs from the microvasculature (where angiogenesis takes place) is 10–15 times higher than that on 
ECs from the macrovasculature [40], supporting their role in the process of neovascularization (further 
discussed in Section 3). As HSPGs, also heparin, secreted during inflammation, exerts a variety of 
effects including the regulation of coagulation (through the binding to factors such as antithrombin III 
and heparin cofactor II [41]) and the regulation of neovascularization (further discussed in Section 3). 
The modulations imposed by heparin/HSPGs to the process of neovascularization can diverge 
greatly, ranging from stimulation to inhibition, mainly depending on the free, cell- or ECM-associated 
nature of the sugar taken in consideration: cell-associated HSPGs usually act as (co)receptors for AGF, 
triggering and/or enhancing the process of neovascularization. The same also holds for ECM-associated 
HSPGs, that act as a reservoir of AGFs and protect them from proteolytic degradation. At variance, the 
free forms of HSPGs, as well as heparin, sequester AGFs in the extracellular environment, hampering 
their interaction with ECs and thus exerting an inhibitory effect on angiogenesis [42]. 
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3. Molecular Bases and Biological Sequences of the Interaction of Heparin/HSPGs with 
Angiogenic Modulators 
As already stated, the capability of heparin/HSPGs to regulate angiogenesis relies on their binding 
to AGFs, pro-angiogenic receptors, antiangiogenic factors and angiogenesis effectors (Table 1). At  
a molecular level, the sulfate groups of GAG are almost always responsible for the interaction with 
heparin-binding proteins. As described above, heparin/HS structure is characterized by a high sulfation 
heterogeneity that generates discrete GAG sequences recognized by different proteins. The decoding of 
the specific GAG sequences involved in the interaction with AGFs has been eagerly pursued but only 
seldom achieved (as in the selected cases of the antithrombin-binding [43,44] and of the FGF2-binding [45] 
saccharides sequences of heparin, further discussed below). Although the development of powerful 
novel technologies will surely help in the better understanding of principles governing specificity of 
HS interactions with proteins [44,46], it is now widely accepted that protein recognition by GAGs is 
relatively nonselective with sharing/overlap of saccharidic sequences [47,48]. Accordingly, rather than 
the decoding of specific sequence, the preferential involvement of sulfate groups in the interaction of a 
given AGF has been established (Table 2). Originally, the search for specific GAG sequences 
responsible for distinct interactions was functional to the design of heparin-like drugs with selected 
binding capability. Today however it is widely accepted that a relatively nonselective binding would 
confer to heparin-like drugs a higher antiangiogenic efficiency since, as already stated, angiogenesis is 
almost always the outcome of the simultaneous action of different AGFs. 
Sulfate groups of GAGs almost invariably bind to specific basic domains present within the  
amino acid sequence of the proteins (Table 3). Basic domains can consist of either linear amino acid 
sequences or conformational domains formed by non-contiguous basic amino acids. Multiple basic 
domains can sometimes be found in the same protein, as in HGF (Table 3). Within the basic domains, 
a tight correlation exists between their affinity for heparin and the spatial arrangement of the positive 
charges [49]. The sequencing of the basic domains of AGFs may help in the design and production of 
peptides or peptidomimetics able to specifically mask HSPGs to a given AGF. 
The angiogenic process can be usefully represented as a “connectivity map”, in which the different 
modulators are tightly connected to heparin/HSPGs and among themselves (Figure 3). Connectivity 
maps are functional to the decoding of the “angiogenesis glycomic interactome”, whose usefulness is 
sustained by the works by Nunes et al., that explored the changes in heparin interactome in healthy and 
pathological pancreas for potential biomarkers [50]. Looking to Figure 3, heparin/HSPGs emerge as 
highly linked “hub molecules” exploitable as target/templates for the development of therapeutics 
aimed at the inhibition of neovascularization in angiogenesis-dependent diseases. Here below, the 
structural features of the interaction of heparin/HS with the most important angiogenic modulators are 
reported along with the main biological consequences of such interactions. 
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Table 1. Canonical and non canonical AGFs, pro-angiogenic receptors, antiangiogenic 
factors and angiogenesis effectors that bind to heparin/HSPGs. 
Canonical AGFs Reference 
VEGF-A [51] 
FGFs [52] 
angiopoietins [53] 
angiogenin [54] 
PlGF [55] 
platelet-derived growth factor (PDGF) [56] 
midkine/pleiotrophin [57] 
heparin-binding EGF-like growth factor (HB-EGF) [58] 
angiomodulin (AGM/TAF/mac25) [59] 
Non Canonical AGFs and Other Regulators 
gremlin [60] 
transforming growth factor (TGF)-β [61] 
hepatocyte growth factor (HGF) [62] 
bone morphogenetic proteins (BMPs) [63] 
interferon (IFN)-γ [64] 
TNFs [65] 
granulocyte monocyte colony stimulating factor (GM-CSF) [66] 
CXCL8 [67] 
CCL2 [68] 
CCL5 [69] 
CXCL12 [70] 
HIV-1 Tat [71] 
HIV-1 p17 [72] 
pregnancy-specific β1 glycoproteins (PSGs) [73] 
α-ATP synthase [74] 
HMGB-1 [17] 
CYR61 [75] 
YKL-40 [76] 
osteoprotegerin (OPG) [77] 
FN [18] 
fibrinogen/fibrin (FB) [78] 
heparin cofactor II [79] 
FXa [20] 
Pro-Angiogenic Receptors 
VEGFR2 [80] 
FGFR1, 2, 3,4 [81–85] 
neuropilin (NPR)-1 [10] 
Robo [86] 
integrin α5β1 [87] 
integrin αvβ3 [88] 
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Table 1. Cont. 
Angiogenic Inhibitors Reference 
thrombospondin-1 (TSP-1) [89] 
endostatin [87] 
CXCL4 [90] 
histidine rich glycoprotein (HRGP)  [91] 
protamine [92] 
CXCL10 [93] 
pigment epithelium-derived factor (PEDF)  [94] 
endothelial monocyte-activating polypeptide-II (EMAP II) [74] 
tissue inhibitor of metallo proteinases (TIMP)-3 [95] 
laminin (LM) [96] 
serpin protease nexin-1 (PN-1) [97] 
plasminogen activator inhibitor type 1 (PAI-1)  [98] 
HS-binding protein HIP/RPL29 [99] 
antithrombin [100] 
Effectors 
sulfatase SULF-1 [101] 
heparanase [102] 
tissue and urokinase-like plasminogen activators [103] 
plasminogen [104] 
3.1. Positive Regulators (Canonical, non-Canonical AGFs, Their Receptors and Effectors) 
In this review, the term canonical AGFs refers to those AGFs that has been originally discovered for 
their direct, pro-angiogenic potential (i.e., VEGFs and FGF2). The term non canonical AGFs refers 
instead to cytokines, viral proteins or other molecules that, although discovered and long studied  
for their roles in processes such as inflammation, coagulation or viral infections, has been then 
incidentally demonstrated to be endowed with the capacity to regulate also the process of 
neovascularization (further detailed below). Despite their different origin and roles, many of the 
canonical and non canonical AGFs present basic domains within their amino acid sequences (Table 3), 
being thus endowed with heparin-binding capacity (Tables 1 and 2). 
As mentioned above, the various VEGF-A isoforms differ by the presence or absence of a short 
heparin-binding domain localized into its C-terminal 55 residues (Table 3). In details, VEGF121 isoform 
lacks the heparin-binding domain and does not bind HSPGs, being found mainly as a free protein in 
body fluids. VEGF189 is instead found mainly tethered to the HSPGs of the ECM in an inactive  
form and its enzymatic activation generates an active form (VEGF110) lacking the heparin-binding 
domain [105]. VEGF165 interacts with heparin with a Kd equal to 11–80 nM [106,107]. It also binds to 
HSPGs that act as coreceptors for its subsequent interaction with VEGFR2 [108]. Although all the 
sulfate groups of heparin contribute to the interaction with VEGF-A, 6-O-sulfate groups appear to be 
particularly important. An hexa/eptasaccharide is sufficient to bind a VEGF165 monomer [51]. 
Heparin and free HSPGs can exert opposite effects on VEGF165: low and high molecular weight 
heparins inhibit and potentiated VEGF165 binding to its receptors, respectively [109]. Accordingly,  
in vivo, administration of low molecular weight heparins suppress VEGF165-mediated angiogenesis, 
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shortening the number and length of microvessel sprouts, while high molecular weight heparin 
significantly elongate microvessel [110]. Also, heparin and HS increase or inhibit VEGF165-binding to 
its receptors [111] and the consequent EC proliferation and migration [112] when administered at low 
and high doses, respectively.  
Table 2. Sulfate groups of heparin/HS primarily involved in the interaction with selected 
angiogenic modulators.  
AGF Sulfate Groups Reference 
VEGF-A  6-OSO3  [51,113] 
FGF2 2-OSO3  NSO3 [45,114] 
PlGF 2-OSO 6-OSO3  [115] 
HGF  6-OSO3  [116] 
TGF-β   NSO3 [117] 
PDGF 2-OSO 6-OSO3 NSO3 [56] 
midkine   NSO3 [118] 
angiomodulin 2-OSO3 < 6-OSO3 <NSO3 [119] 
HB-EGF  6-OSO3  [120] 
gremlin 2-OSO3 6-OSO3 NSO3 [60] 
HIV-1 Tat 2-OSO3 6-OSO3 NSO3 [121] 
HIV-1 p17 2-OSO3 6-OSO3 NSO3 [72] 
CXCL8 2-OSO 6-OSO3 NSO3 [122] 
CXCL12 2-OSO3  NSO3 [123] 
IFN-γ   NSO3 [124] 
CCL2    6-OSO3 [125] 
CCL3 2-OSO 6-OSO3  [126] 
CCL21 2-OSO3 6-OSO3  [127] 
Pro-Angiogenic Receptors 
FGFR1, FGFR4  6-OSO3  [85,128] 
NRP-1  6-OSO3  [129] 
Natural Angiogenic Inhibitors 
TSP-1   6-OSO3   NSO3 [130] 
endostatin  6-OSO3   [131,132] 
TIMP-3 2-OSO3   NSO3 [95] 
Effectors 
heparanase   NSO3 [133] 
FN 2-OSO >>6-OSO3 >NSO3 [134] 
The interaction of heparin/HSPGs with FGFs occurs with Kd values spanning from 2 to 600 nM [135]. 
X-ray crystallography has identified a number of basic amino acids (Table 3) that form a “basic task” 
in the 3D structure of FGF2 that interact with 1–2 sulfate groups of heparin [136]. Six hexose residues 
of heparin are sufficient to bind 1–2 molecules of FGF2 [45]. The specific FGF2-binding sequence in 
HS is represented by a pentasaccharide containing the disaccharide units IdoA2S-GlcNS or  
IdoA2S-GlcNS6S [45], with 6-O-sulfate groups necessary however to promote FGF2/FGFR 
interaction [128]. Accordingly, although a pentasaccharide is enough to bind FGF2, a decasaccharide 
is required to exert a modulatory effect on the AGF [137], supporting the hypothesis that 
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heparin/HSPGs, FGF2 and FGFR1 form a ternary complex in which the GAG chain interacts with 
FGF2 via 2-O-sulfate and N-sulfate groups and with FGFR via 6-O-sulfate groups [138]. FGF2 
binding to EC-surface HSPGs promotes angiogenesis in vitro and in vivo [1,139] by direct activation 
of intracellular signaling [140], by mediating FGF2 internalization [141], by presenting FGF2 to 
FGFRs in a proper conformation or by promoting the formation of the productive HSPG/FGF2/FGFR1 
ternary complex [1,139]. ECM-associated HSPGs act as a reservoir for FGF2 for long-term stimulation 
of ECs [142]. Also, ECM degradation leads to mobilization of entrapped FGF2 with consequent 
activation of angiogenesis [143]. Heparin and free HSPGs bind FGF2 and protect it from heat and 
acidic inactivation [144] and from proteolytic degradation [145]. Also, free GAGs favor the delivery of 
FGF2 to the blood supply increasing its radius of diffusion [146]. At the EC-surface, heparin induces 
oligomerization of FGF2 [147] that is required for its full biological response [148]. Depending on its 
concentration, heparin can instead act as an antagonist, binding and sequestering FGF2, hampering its 
interaction with the ECs and inhibiting its biological activities [149]. 
Table 3. Basic domains driving the interaction of angiogenic modulators with sulfated GAGs.  
AGF Basic Domain Sequences Reference 
VEGF-A R123R124R159 [150] 
FGF2 
K35R53K128R129K134K138K144 
K26N27R81K119R120T121Q123K125K129Q134K135 
[151,152] 
FGF1 N18K112K113N114 [153] 
midkine K79R81K86 K87R89K102 [154] 
angiomodulin K89SRKRRKGK97 [59] 
HGF K60K62R73R76 K78   R512-R-K516   H645HR-K649 [155–157] 
angiogenin R31RR33 [54] 
CXCL8 H23K25K28K59R65K69K72 [158] 
INF-γ K128RKR131 [159] 
HIV-1 Tat R46KKRRQRRR61 [71] 
HIV-1 p17 K26KKYKLKH33 [72] 
TGF-β1 R18R25K26K31H34K37        K60R94K97R107K110 [117,160] 
GM-CSF H15H83H87 [161] 
HB-EGF K21RKKKGK27     K31KR33     R38KYK41 [162] 
CCL2 K5H66 [163] 
Slit R461R462K466R467K472K475 [164] 
Pro-Angiogenic Receptors 
FGFR1 K160K163K164H166K172H201K225 [165] 
FGFR2 K161MEKRLHAVPAANTVKFR178 [153] 
integrin αvβ3  αv subunit: R65K446K489K520K535K645K646  K151 [88] β3 subunit: 
Angiogenic Inhibitors 
CXCR4 K77NGR80   R51PRH54   K62   K92KIIKK97 [166] 
endostatin R27R139 [167] 
antithrombin K115 K125 [43] 
Effectors 
heparanase K158KFKN162 [168] 
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Figure 3. Representative angiogenesis connectivity map. Heparin/HSPGs can be ideally 
put at the centre of the angiogenesis connectivity map, emerging as a highly connected hub 
molecules. Dotted lanes indicate the mutual interaction among the various angiogenesis 
modulators. Green and red colours indicate a pro-and antiangiogenic effect, respectively. 
Angiogenin binds to heparin and EC-associated HSPGs, with X-ray crystallography suggesting  
that sulfate groups of heparin/HSPGs are involved in the interaction [169]. Accordingly, a basic 
domain has been identified in angiogenin (Table 3). The binding to heparin induces angiogenin 
oligomerization [54] and protect it from proteolytic degradation [170]. The binding to HSPGs causes 
instead angiogenin nuclear translocation of, required for its angiogenic activity [170]. Angiopoietin 
like-4 binds to heparin and HS with affinities ranging from 20 to 376 nM [135]. Functionally, the 
binding of angiopoietin-3 to EC-surface HSPGs induces retraction and loss of integrity of the EC 
monolayer without hampering its binding to Tie2 receptor [53]. Angiomodulin is a 30-kDa glycoprotein 
highly accumulated in small blood vessels of tumors that promotes capillary tube-like structures from 
vascular ECs [59]. Heparin and HS and heparinase treatment inhibits angiomodulin binding to cells, 
pointing to HSPGs as major receptors for angiomodulin-dependent pro-angiogenic activity. Midkine 
and pleiotrophin bind strongly to HS with a Kd equal to 6–16 nM [135]. In midkine, two C-terminal 
domains mediate the binding to heparin (Table 3), while on the GAG, all the sulfate groups contribute 
to the interaction, with N-sulfate groups resulting to be critically important (Table 2). Heparin 
mobilizes midkine in the blood stream from their EC-associate storage [171] and protects it from 
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proteolytic degradation [172]. At the EC-surface, midkine binds to HSPGs with a Kd equal to 0.2 nM, 
being this interaction responsible, at least in part, for its angiogenic activity [173].  
The bone morphogenetic protein antagonist Drm/gremlin exerts pro-angiogenic activity [174]. It 
binds heparin with a Kd equal to 20 nM via N-, 2-O, and 6-O-sulfate groups [60]. Gremlin also binds 
HS but not other GAGs. Accordingly, gremlin binds HSPGs of the EC surface, mediating VEGFR2 
engagement and autophosphorylation, ERK1/2 and p38 activation, and consequent pro-angiogenic 
responses of ECs to gremlin [60]. 
HGF/c-met interaction induces angiogenesis [175] and binds to heparin and HS with Kd values 
ranging between 0.2 and 12 nM [135]. The interaction depends on basic domains present both in the  
N- and C-terminus of HGF (Table 3) that are distinct from the c-met binding domain [176], suggesting 
that HGF, HSPGs and c-met form a ternary complex. The HGF-binding sequence in HS contains  
two units of IdoA2S-GlcNS6S contiguously or alternately close to of the reducing end [177], with  
6-O-sulfate groups playing the most important role in the binding (Table 2). The minimal length of 
heparin that retains a HGF-binding capability is an hexa/octasaccharide, but the highest affinity  
is found with GAGs containing 10–12 monosaccharide units [177]. Heparin induces the release of 
bioactive HGF [178]. Also, heparin/HSPGs promote HGF oligomerization and HGF-dependent c-Met 
activation [179] increasing its mitogenic potency [179]. Immobilized heparin retains its capability to 
bind HGF that, in turn, retains its capability to stimulate DNA synthesis in adherent cells, suggesting 
that HGF can be trapped in the ECM via HSPG acting as a localized mitogen for adherent cells [180]. 
Although the data summarized above have been derived from cells other than endothelium, the 
possibility that HSPGs act as pro-angiogenic receptors for HGF on ECs has been inferred [155]. 
HIV-1 Tat is a HIV-1 encoded pro-angiogenic peptide [181] that binds heparin with a Kd equal to 
5–64 nM [182,183]. It contains a basic domain composed by a linear stretch of positively charged 
amino acids (Table 3) mainly responsible for its interaction with heparin that, in turn, requires sulfation 
of the 2-O-, N-O-, and 6-O-positions (Table 2). An hexasaccharide is the minimal size that retains  
Tat-binding capability. However, the affinity of binding increases with increasing the length of the 
GAG, with fragments up to 18 saccharides approaching the affinity of full-size heparin [184]. Heparin 
can exert both agonist and antagonist effects on Tat. Indeed, it induces Tat oligomerization [184], 
protects it from proteolytic degradation [185] and mobilizes it from cell-associated HSPGs [185]. 
However, high concentrations of heparin compete with cellular receptors for Tat interaction exerting 
an inhibitory effect [121]. The implication of heparin/HSPGs in Tat angiogenic activity is sustained by 
the observation that HSPG-like low affinity, high capacity binding sites for Tat are present on ECs [186] 
and heparin inhibits Tat pro-angiogenic activity [187]. 
PSGs are the most abundant fetal proteins in the maternal bloodstream in pregnancy. PSG1 exerts  
a pro-angiogenic activity that depends on the presence of GAGs on ECs [73]. Accordingly, PSG1 does 
not bind to cells lacking surface expression of HSPGs and the binding can be restored by transfection 
with syndecans or glypican-1. Also, the removal of cell surface GAGs or competition with heparin 
completely inhibited PSG1 binding to target cells [73].  
The interaction of Slit with transmembrane receptors of the Robo family provides important  
signals in tumor metastasis and angiogenesis. HSPGs have been demonstrated to serve as essential  
co-receptors in Slit signaling, by stabilizing a ternary complex in which GAG chains of HSPGs  
bind simultaneously with the ligand and the receptor [164]. YKL-40 is a secreted heparin-binding 
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glycoprotein associated with a worse prognosis of various advanced human cancers. It promotes 
angiogenesis in vitro by coordinating syndecan-1 and integrin αvβ3 on the EC surface thus activating 
FAK and ERK1/2 [76]. Osteoprotegerin (OPG) promotes angiogenesis in vivo mainly through  
a SDF-1/CXCR4 dependent pathway, but a role of syndecan-1 has been also inferred [77]. 
Apart from the canonical and non-canonical AGFs listed above, for which a correlation between 
heparin-binding capacity and pro-angiogenic activity has been already established, many other molecules 
have been studied separately for their binding to heparin/HSPGs and for their pro-angiogenic potential, 
so that the possible relationships between the two events represents open fields of research. The 
PDGFs are disulfide-bonded dimers of short or long isoforms of A and B polypeptides, with the short 
isoforms lacking the heparin-binding basic C-terminal domain [188]. The different PDGF isoforms are 
then differently entrapped in the ECM after their release by ECs [189]. Studies using desulfated 
heparins and heparin fragments suggest that N-, 2-O-, and 6-O-sulfate groups equally contribute to the 
interaction (Table 2) and that the shortest heparin fragment retaining PDGF binding capability consists 
of 6–8 monosaccharide units. Heparin amplifies PDGF-BB-induced PDGF-α but not -β receptor activation 
in HSPGs-deficient cells [190]. The involvement of TGFs in vascular function are manifold [191]. 
TGF-β1 and -β2, but not -β3 bind heparin/HSPGs [117]. In TGF-β1, two potential heparin-binding sites 
have been identified (Table 3). HS endowed with a low degree of sulfation do not potentiate TGF-β1 
biological activity, indicating the involvement of the sulfate groups of GAGs in the interaction (Table 2). 
Free GAGs protect TGF-β1 from proteolytic degradation [192] and increase its biological activity by 
dissociating the growth factor from the inactivating α2M complex [117]. At the cell-surface,  
HSPGs acts as a co-receptor facilitating TGF-β1 interaction with its type II receptor. At variance,  
when naturally shed, free HSPGs sequester TGF-β1 inhibiting its biological activity [193]. The  
pro-angiogenic [194] CCL2 binds to heparin with low affinity (Kd = 1.55 μM) [195]. The binding 
occurs only with highly sulfated oligosaccharides [196], with the specific contribution of the single 
sulfate groups not yet assessed. An octasaccharide is the minimal heparin sequence that retains  
the capability to bind CCL2 inducing its dimerization [195]. CCL2 also binds to HSPGs present on 
EC-surface [197] and in endothelial ECM [198]. The heparin-binding domain of IFN-γ is located in its 
C-terminus (Table 3), while the IFN-γ binding domain in HS is composed of a domain predominantly 
N-acetylated and flanked by small N-sulfated oligosaccharides [159]. An hexa/octasaccharide can 
accommodate an IFN-γ dimer [159]. The binding to heparin protects IFN-γ from proteolytic degradation 
decreasing its blood clearance [199]. Heparin also prevents IFN-γ interaction with EC-surface  
HSPGs [200]. P17 is another HIV protein endowed with angiogenic potential [201]. An integrated 
approach including computational modeling, site-directed mutagenesis, chemical desulfation of heparin, 
and surface plasmon resonance was employed to characterize the interaction of p17 with heparin, that 
resulted to occur with a Kd equal to 190 nM [72]. The 2-O-, 6-O-, and N-O sulfate groups of heparin, 
seem to contribute equally to the binding to p17 (Table 2). Two basic motifs are present in the N and C 
termini of p17 and neutralization (Arg→Ala) of the former, but not of the latter, causes the loss of  
p17 heparin-binding capability. The N-terminal heparin-binding motif of p17 partially overlaps the 
CXCR1-binding domain. Accordingly, its neutralization also prevents p17 binding to the chemochine 
receptor. P17 binds HSPGs, but, to date, this interaction has been tentatively associated only to  
p17-driven cytokine up-regulation in lymphocytes [202,203]. Heparanase is an endoglycosidase that, 
acting on heparin and HSPGs [102] mobilizes entrapped AGFs, inducing angiogenesis with an indirect 
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mechanism of action. However, heparanase also promotes cell adhesion, survival and signaling  
events independent of its enzymatic activity, suggesting that it may regulate angiogenesis by multiple 
mechanisms [19]. GM-CSF is a pro-angiogenic cytokine [204]. It binds heparin via a basic domain 
(Table 3) that interacts with sulfate groups of the GAGs [205]. Also TNF-α binds heparin [206]  
and cell-associated HSPGs [207], but the relevance of these interactions in its capability to induce 
angiogenesis [208] remains elusive. CYR61 is a cysteine-rich, heparin-binding protein that, once 
secreted, acts as an ECM-associated signaling molecule contributing to physiologic and pathologic 
neovascularization [75]. α-ATP synthase is a pro-angiogenic peptide that binds HS and whose activity 
can be inhibited by the natural antiangiogenic EMAP II [74] (further discussed below). 
Beside free AGFs, heparin and HSPGs also bind some pro-angiogenic receptors associated to the 
surface of ECs: heparin and HSPGs bind VEGFR2 [209] and VEGFR1, stabilizing the productive 
ternary complex with VEGF-A at the EC-surface [210]. The binding of FGFRs with heparin/HSPGs 
has been the subject of a huge amount of work: FGFR1, 2, 3 and 4 bind heparin with affinities ranging 
between 66 nM and 3.2 μM [135]. As already reported above, 6-O-sulfate groups of heparin mediate 
its binding to FGFR1 [128]. Integrins α5β1 and αvβ3 bind to heparin/HSPGs through their extracellular 
domains [87]. Functionally, this interaction leads to the activation of FAK, Src, paxillin and  
ERK1/2 [211], but the impact of such events on angiogenesis has not been elucidated yet. NPR-1 is  
a multidomain receptor involved in both the development and maintenance of normal vasculature and 
pathological angiogenesis. It interacts with a complex network of other membrane receptors, including 
HSPGs, and their respective ligands. NPR-1 can be shed as a short form composed of its extracellular 
domain. Both membrane-associated and free forms of NRP-1 bind heparin, with possible, still unexplored, 
biological consequences [129]. Robo binds heparin with low affinity (Kd equal to 650 nM) [86], the 
consequences of such interaction have been already described above for its ligand Slit. 
3.2. Modulators with Opposite Effects 
TSP-1 is a modular, matricellular protein that regulates cell interactions with the environment. 
Through its different domains, TSP-1 interacts simultaneously with different cell receptors, soluble 
cytokines and growth factors, ECM components, and proteases. This accounts for the pleiotropic 
nature of TSP-1, which, depending on the relative presence of its different ligands, can induce opposite 
effects on angiogenesis. TSP-1 inhibits angiogenesis both indirectly (by binding and sequestering 
different AGFs or by masking HSPGs to their interaction) and directly (by interacting with specific EC 
receptors) [212]. The heparin binding domain of TSP has been located at the N-terminus of the protein 
and demonstrated to effectively bind syndecan-4, possibly transducing a pro-angiogenic effect rather 
than an inhibitory one [213,214]. 
Endostatin, a heparin-binding fragment of collagen XVIII, binds to heparin with low affinity (Kd 
values ranging between 1 and 25 μM [135]). It is a multifaceted molecules that exerts multiple, even 
opposite functions in angiogenesis depending on its monomeric or trimeric state: trimeric endostatin 
induces a pro-migratory phenotype in ECs that is inhibited by exogenous GAGs in a size-dependent 
manner, with heparin oligosaccharides containing more than 20 monosaccharide residues having 
optimal inhibitory activity. Monomeric endostatin inhibits instead angiogenesis induced by its trimeric 
counterpart or by FGF2 and VEGF-A by competing for the binding to HSPGs [215,216]. 
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CXCL8 is a major regulator of angiogenesis during inflammation [217]. In silico docking of  
a heparin hexasaccharide to CXCL8 [158] involved a conformational basic domain (Table 3). 
Contrasting results have been obtained for the interaction of heparin with the monomeric or dimeric 
forms of CXCL8: one study demonstrated that both the forms bind to heparin with high and low 
affinity, respectively, with the highest affinity displayed by monomeric CXCL8 interacting with a HS 
octamer (Kd < 5 nM) [218]. Another study demonstrated instead that the affinity of monomeric 
CXCL8 for heparin/HS is too weak to allow binding at physiological ionic strength, whereas dimeric 
CXCL8 mediates binding to two sulfated domains of HS enriched with di-O-sulfate disaccharide  
unit IdoA2S-GlcNS6S- [122]. At a functional level, the binding to heparin stabilizes CXCL8, thereby 
prolonging its biological effect [218], and promotes its oligomerization [219]. A direct binding  
of CXCL8 to HSPGs on ECs has been demonstrated [220,221] but with no clear association to  
a pro-angiogenic effect. Rather, endothelial HSPGs are required for CXCL8 to exert its antiangiogenic 
activity directed toward FGF2 [222]. 
The heparin-binding domain of FN induces pro-angiogenic activation of ECs that is inhibited by 
heparin. An increase in the expression of VEGF-A is observed in FN-stimulated ECs, suggesting  
an indirect mechanism of action [18]. On the other hand, HSPGs serve as receptors for the first type III 
repeat of fibronectin that inhibits angiogenesis [223], suggesting that FN, as other modular protein  
can exert both pro- or antiangiogenic effects. Fibrinogen/fibrin (FB) exerts different effects on 
neovascularization by interacting with a wide array of AGFs, effectors, angiogenic inhibitors (i.e., 
HRGP) and pro-angiogenic receptors [78]. FB binds heparin and HSPGs [224], inferring that these 
interactions may mediate at least some of its pro- or antiangiogenic effects. HB-EGF is a member of 
the EGF family expressed by many cell types including ECs that has been demonstrated to both induce 
angiogenesis [120] and to exert an antiangiogenic effect by binding to EC-surface HSPGs [225].  
The extracellular sulfatases Sulf1 and Sulf2 bind to heparin with Kd values ranging between 0.6 and  
17 nM [101]. They act by remodeling the 6-O-sulfation state of HSPGs on the ECs surface and 
ameliorating the signaling of AGFs [101,226]. However, Sulf1 has been also reported to exert  
an antiangiogenic effect [227], calling for further studies aimed at explaining these contrasting results. 
3.3. Natural Angiogenic Inhibitors 
Protamine is a small DNA-binding cationic protein that interacts with HSPGs [228], concealing 
these receptors to FGF2 and FGF1 [92]. Accordingly, it inhibits FGF2-dependent angiogenesis  
in vitro [229] and in vivo [230]. HRGP and kallistatin are heparin-binding proteins that inhibit  
EC adhesion, proliferation, migration and morphogenesis induced by VEGF-A and FGF2 in vitro  
and in vivo [231]. In both the proteins, the heparin-binding and the antiangiogenic domains  
co-localize [232,233], suggesting that their antiangiogenic potential depends, at least in part, by  
their capability to bind HSPGs. PEDF is a collagen-binding protein abundantly distributed in various 
tissues that exhibits various biological functions, including the capability to inhibit angiogenesis.  
It directly interacts with HSPGs and its binding to collagen I is inhibited by heparin, pointing to  
a functional relationship between PEDF and heparin/HSPGs during angiogenesis [94]. CXCL10  
exerts angiostatic activity in vivo and inhibits FGF2-induced EC proliferation and migration [217].  
The possibility that the binding to HSPG is responsible for its antiangiogenic activity is suggested by 
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the presence of specific HSPG binding site in ECs and by the observation that its capability to inhibit 
EC proliferation is abrogated by heparin [234]. Antithrombin inhibits neovascularization by blocking 
FGF2 and VEGF-A from forming ternary complexes with their TKRs and HSPGs. The specific 
heparin-binding site of antithrombin (Table 3) has been identified [44] and found to be essential for its 
antiangiogenic activity [43]. Also, antithrombin inhibits only the heparin-binding VEGF165 but not the 
shorter isoforms VEGF121 [100]. Finally, treatment of ECs with heparinase III suppress the ability of 
antithrombin to inhibit AGF-dependent proliferation. EMAP-II is an antiangiogenic factor containing 
an heparin binding motif that exerts an inhibitory effect by competing with pro-angiogenic α-ATP 
synthase [74]. PN-1, a protease expressed by ECs, exerts an antiangiogenic effect that does not depend 
on its anti-protease activity but involves its binding to HSPGs [97]. CXCL4 binds heparin with a Kd 
equal to 160 nM [135] and inhibits neovascularization by binding and masking HSPGs [235] and by 
directly binding AGFs such as FGF2 [236] and VEGF-A [237]. 
In conclusion, an impressive number of molecules can modulate angiogenesis by binding to heparin 
and HSPGs. The effect exerted (stimulation or inhibition) depends on both intrinsic features of the 
protein (i.e., modular proteins such as TSP-1, FB, FN that act as scaffold to set up multimolecular 
aggregates with heparin/HSPGs) and the free, cell- or ECM-associate nature of the sugar. In general, 
heparin/free HSPGs act as antagonists, sequestering AGFs in the extracellular environment. Conversely, 
EC-associated HSPGs exert a pro-angiogenic effect by acting by different mechanisms: (i) direct 
triggering of a signal transduction pathway in response to AGF engagement; (ii) AGFs internalization; 
(iii) presentation of AGFs to their TKRs in an optimal configuration. ECM-associated HSPGs act as  
a reservoir for AGFs that reach higher local concentration and sustain the long-term stimulation of 
ECs. Finally, some natural angiogenic inhibitors bind to EC-associated HSPGs inducing apoptosis or 
decreasing ECs responsiveness to AGFs. Interestingly, the synthesis [238] and/or mobilization [239] of 
HSPGs in ECs is regulated by AGFs and angiogenic inhibitors, increasing the intricacy of the system. 
A schematic representation of the complex interplay existing between heparin/HSPGs and the angiogenesis 
machinery is shown in Figure 4. 
4. Therapeutical Exploitation of the Heparin/HSPGs Glycomic Interactome 
Due to recent improvements in glycomics [240], protein-glycan interaction have been always more 
taken in consideration for the design of novel therapeutic approaches. Accordingly, an equally growing 
number of novel glycan-based drugs entered preclinical and clinical studies [241]. The heparin/HSPGs 
system can be exploited to block angiogenesis in three main ways (Figure 5): (i) heparin-binding basic 
domains represent “templates” for the design and production of “decoy” compounds that bind and 
mask EC-surface HSPGs; (ii) heparin/HS represent “templates” for the design and production of drugs 
that, sequestering the AGFs in the extracellular environment, prevent their interaction with ECs and 
inhibit their pro-angiogenic effect; (iii) HSPGs can be masked to AGFs or removed, their expression 
can be inhibited or their composition can be modified in a form lesser recognizable by AGFs. Here 
below, a representative list of antiangiogenic compounds acting by the different mechanisms listed 
above will be reported.  
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Figure 4. Heparin/HSPGs and the angiogenic machinery: (1) heparin/free HSPGs 
sequester AGFs hampering their interaction with ECs. (2) AGFs bind HSPGs of the ECM, 
increasing their concentration in proximity of ECs. ECM-associated AGFs are mobilized 
for EC long-lasting stimulation that occurs by different mechanisms: EC-associated 
HSPGs present AGFs to TKRs that, in turn, transduce pro-angiogenic signals in ECs (3). 
HSPGs themselves directly transduce pro-angiogenic signals following their engagement 
by AGFs (4). These same signals regulate the surface expression of HSPGs (5) or the 
production of proteases/glycosidases (6) that generate free HSPGs (7). Finally, by binding 
EC-associated HSPGs, antiangiogenic modulators can transduce negative signals that 
inhibit ECs activation (8).  
4.1. Compounds that Bind to HSPGs 
An approach for the development of antiangiogenic compounds consists in the identification of the 
heparin-binding domain of an AGF and the production of related synthetic peptides endowed with  
the capability to bind and mask HSPGs to the native AGF. The FGF2-mimicking synthetic peptide 
F2A4-K-NS has been produced that is able to bind and mask HSPGs to the parental AGF [242].  
A synthetic peptide corresponding to exon 6a of VEGF-A binds HSPGs preventing VEGF-A interaction 
with the endothelial surface, EC migration and angiogenesis in vivo [243]. The M α5-derived  
peptide A5G27 binds to the GAG chains of CD44, preventing its binding to FGF2 and inhibiting 
angiogenesis [96]. Peptides from the heparin-binding domains of HGF (Table 3) inhibit angiogenesis 
independently from binding to c-met receptor [156]. The basic domain of HIV-1 Tat has been used to 
produce multi-valent BSA conjugates that exert antiangiogenic activity by binding not only to HSPGs 
but also to VEGFR2 and integrins [182]. The synthetic peptides P(65–97) from the C-terminus of 
pleiotrophin inhibits the angiogenic activity of pleiotrophin and FGF2 by virtue of its ability to bind 
heparin so to compete with the growth factors for EC-associated HSPGs [244]. LfcinB is a fragment of 
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heparin-binding lactoferrin that inhibits angiogenesis by both FGF2 and VEGF-A by binding to 
HSPGs of ECs [245]. Several CXCL4-derived peptides exhibit antiangiogenic properties [246], whose 
mechanism of action may rely, at least in part, on their capability to bind and mask HSPGs to AGFs.  
It can not be ruled out that, beside masking HSPGs to AGFs, some of the compounds that bind  
HSPGs may also directly transduce antiangiogenic signals inside ECs. This may be the case of  
the CXCL4-derived peptides mentioned above [246] and of LD22-4, an 86-amino fragment of FGF2 
that suppresses angiogenesis in vivo. Although its action is mainly mediated by NRP-1, it also contains 
an heparin-binding domain and requires HS for its binding to cells, inferring a possible contribution of 
this latter interaction to its antiangiogenic activity [247]. 
 
Figure 5. Heparin/HSPGs-related strategies to inhibit angiogenesis: from left to right:  
EC-surface HSPGs can be masked to AGFs by means of HSPGs-binding decoys; 
compounds based on natural antiangiogenic molecules can decrease EC responsiveness to 
AGFs or can induce EC apoptosis; heparin-like molecules can sequester AGFs, preventing 
their interaction with ECs or can bind and mask TKRs; some compounds decrease the 
expression or the sulfation degree of HSPGs at the EC surface; other can be used to 
directly remove HSPGs. 
4.2. Heparin-Like Compounds that Bind AGFs 
This is by far the most investigated area of antiangiogenic drug discovery. Since prototypic heparin 
cannot be used as a drug due to its anticoagulant activity, countless studies have been performed aimed 
to dissociate its antiangiogenic potential from its anticoagulant activity, leading to the development of a 
wide array of heparin-like candidate drugs (Table 4). VEGF-A has been considered as a main target for 
the development of VEGF-A-binding antiangiogenic polyanionics. Also, the possibility to block FGFs 
by means of heparin-like compounds raised particular interest since FGFs are pleiotropic molecules 
that, beside angiogenesis, directly stimulate tumor cell proliferation, a feature that can be appropriately 
exploited to gain efficiency in anti-FGFs based anti-cancer therapies (further discussed in Section 5). 
At variance with VEGF-A and FGFs, few data are available about the possibility to block the other 
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AGFs by mean of heparin-like compounds. Again, this is in contrast with the notion that pathological 
angiogenesis is the outcome of the simultaneous contribution from different AGFs [29], calling for 
more extensive comparison of the antiangiogenic potential of heparin-like compounds on a broader 
array of AGFs, functional to the development of drugs endowed with multitarget activity to be employed 
in the treatment of angiogenesis-dependent diseases. 
Table 4. Representative list of heparin-like compounds that bind and inhibit different AGFs. 
AGF Inhibited  Heparin-Like Inhibitor Reference 
VEGF 
chemically modified heparins  [106,110,113,248–253] 
oligosaccharides from seaweed alginic acid [112] 
polysaccharides from Antrodia cinnamomea  [254] 
fucoidan  [255] 
dextran derivatives  [256] 
sucrose octasulfate [107] 
HS mimetic compounds [257] 
heparin-mimetic peptide SY(SO3)DY(SO3)G [258] 
phenylacetate carboxymethyl benzylamide dextran [209] 
phosphosulfomannan (PI-88) and derivatives [107] 
defined GAG sequences from chondroitin sulfate [106] 
low molecular weight fucoidan  [259] 
K5 derivatives [260] 
FGFs 
chemically modified heparins  [37,147,248,250,261,262] 
sulfated beta-(1->4)-galacto oligosaccharides [263] 
sulfated malto oligosaccharides [264] 
Fucoidan [265] 
pentosan polysulfate [266] 
sulfated K5 derivatives  [267] 
suleparoide (HS analogue) [268] 
β-cyclodextrin polysulfate [269] 
Carrageenan [270] 
HS mimetic M402 [271] 
synthetic HS [272] 
sucrose octasulfate [107] 
oligomannurarate sulfate JG3 [102] 
marine sulfated polymannuroguluronate [273] 
sulfated glycoconjugates [274] 
PI-88 and derivatives [107] 
linked sulfated tetracyclitols [275] 
disulfated methyl 6-azido-6-deoxy-a-dmannopyranosides [257] 
Gremlin 
chemically modified heparins, K5 derivatives [60] 
HS mimetic M402 [271] 
chemically modified heparins [276] 
SDF-1α HS mimetic M402 [271] 
chemically modified heparins [248] 
IL-8 chemically modified heparins, PI-88 [107] 
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Table 4. Cont. 
AGF Inhibited  Heparin-Like Inhibitor Reference 
HIV-1 Tat 
K5 derivatives [277] 
pentosan polysulfate  [183] 
dextrin-2-sulphate  [278] 
sulfated polymannuroguluronate [279] 
HIV-1 p17 chemically modified heparins, K5 derivatives [72] 
CXCL8 Fucoidan 
[280] 
CCL2 
Fucoidan 
cyclodextrin sulfate 
[196] 
sucrose octasulfate 
PDGF 
heparin-derived angiogenesis inhibitor LHT7  [251] 
low molecular weight heparins [188] 
TGF-β1 Fucoidan [281] 
IFN-γ HS-derived glycoconjugate mimetics [282] 
BMPs HS mimetic WSS25  [63] 
heparanase N-acetylated glycol split heparin SST0001 [283] 
Another relevant approach to develop heparin-like AGF “traps” devoid of anticoagulant activity  
is the use of non-saccharidic GAG mimetics. The prototype of this class of compounds is suramin,  
a polysulfonated napthylurea that inhibits different AGFs, including VEGF [284], FGF2 [285], and 
angiogenesis effectors such as heparanase [286]. These observations prompted various efforts to 
develop naphthalenesulfonate derivatives endowed with a more specific antiangiogenic profile [287–290]. 
Another interesting class of synthetic non-saccharidic sulfated scaffolds is represented by sulfated 
flavonoids [291] whose antiangiogenic potential has not been fully evaluated yet. Finally, sulfonic acid 
polymers are organic acids that have the strong tendency to bind tightly to proteins and have been 
taken in consideration as antiangiogenic antitumor compounds [292,293]. 
4.3. Heparin-Like Molecules that Bind and Mask Pro-Angiogenic Receptors 
The development of these compounds is based on the observation that, beside AGFs, heparin/HSPGs 
can also bind pro-angiogenic TKRs with important functional consequences (see Section 3.1). In turn, 
this infers the possibility to design heparin-like drugs able to disrupt AGF/TKR interactions thus 
exerting an antiangiogenic effect: phenylacetate carboxymethyl benzylamide dextran binds and inhibits 
NRP-1 [209]. Modified heparins [262,294], sucrose octasulfate [107], PI-88 and its derivatives [107,295] 
bind and inhibit FGFR1. Chemically modified heparins bind and inhibit Robo 1 [86]. Interestingly, 
some heparin-like molecules can bind different receptors simultaneously, suggesting their capability to 
exert a multitarget antiangiogenic activity. This is the case of a marine-derived oligosaccharide sulfate 
that binds VEGFR2, EGF receptor and HER-2/neu [296], and of low molecular weight heparin and 
fucoidan that bind instead both VEGFR2 and NPR-1 [259].  
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4.4. Inhibition of EC-Surface HSPGs Expression 
The proof of concept of this antiangiogenic strategy derives from the observation that antiangiogenic 
anti-thrombin inhibits EC proliferation by down-regulating the surface expression of perlecan [297] 
and that, accordingly, overexpression of perlecan antisense cDNA suppresses the autocrine and paracrine 
functions of FGF2 in fibroblasts [298]. Some chemical compounds have been then produced that 
effectively affect HSPGs expression on ECs with an impact on angiogenesis: a peracetylated 4-deoxy 
analogue of HS inhibits HS expression reducing also HS chain size. As a results, it prevents the 
binding of FGF2 and VEGF-A to ECs-associated HSPGs and inhibits angiogenesis in vivo [299]. Also, 
several fluoro-xylosides derivatives has been developed that inhibit proteoglycan synthesis in ECs 
preventing endothelial tube formation in vitro [300].  
An antiangiogenic effect can be also obtained by modifying the sulfation pattern/degree of HSPGs 
so to decrease their binding to AGFs: sodium chlorate induces the preferential reduction of trisulfated 
disaccharide units of HSPGs, inhibiting VEGFR2 activation by VEGF [301] and gremlin [60] and 
preventing FGF2 binding and mitogenic activity [302,303]. In the same way, the GAG 6-O-endosulfatase 
Qsulf1 inhibits 6-O sulfation of heparin/HSPGs inhibiting neovascularization induced in vivo by  
FGF2 [304], while HSulf-2 inhibits bioavailability of both VEGF and FGF1 [305].  
4.5. Removal of EC-Surface HSPGs 
Depletion of EC-surface HSPGs has been so far obtained by means of the enzymes heparinases or 
heparitinases in controlled experimental conditions: heparinase or heparitinase treatment of ECs reduces 
VEGF interaction [108] and VEGFR2 phosphorylation [301]. Heparinases I and III; but not heparinase II; 
inhibit FGF2-dependent migration [306] and proliferation [307] of ECs in vitro and neovascularization 
in vivo [307]. Finally; heparinase treatment of ECs inhibits internalization of angiogenin; required of 
its angiogenic capability [170]. However; these results remain still without a practical translation to 
antiangiogenic therapy. 
5. Conclusions 
Sugars are more complex than DNA and proteins in terms of chemical structure and information 
density [308]. As a consequence, in respect to genomics and proteomics, glycomics suffered a delay  
in the development of appropriate investigative tools. This is well exemplified in the field of 
angiogenesis, where the proceeding of the molecular characterization of the interaction between AGFs 
and TKRs is far advanced in respect to that the interaction between AGFs and HSPGs. As a result, 
several specific inhibitors of AGFs/TKRs interaction have been developed so far that, however, turned 
out to be of little benefit in the treatment of angiogenesis-dependent diseases, likely because in vivo, 
neovascularization is often the result of the simultaneous actions of multiple AGFs, and the specific 
blockage of one AGF can be easily countervailed by the biochemical redundancy of the process. 
The binding to heparin/HSPGs is a feature shared by all the known AGFs, thus representing  
a promising target for the development of drugs able to interfere simultaneously with multiple AGFs. 
Heparin and HSPGs are characterized by a high structural heterogeneity of GAG-chains that offers 
virtually unlimited possibilities for selective interactions with AGFs. It derives that the identification 
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of specific GAG sequences responsible for the interaction with selected AGFs is an inherently difficult 
task [44]. In the meantime however, the concept that a relatively nonselective binding would confer to 
a heparin-like drug a higher antiangiogenic efficiency came to the limelight, prompting the search for 
“key” structures in GAGs that may help the design and development of multitarget heparin-like drugs. 
A reverse approach is represented by the production of compounds that bind and mask HSPGs to 
different AGFs simultaneously. The feasibility of this latter approach is sustained by the observation 
that synthetic peptides representing the heparin-binding domains of HGF inhibit angiogenesis induced 
in vivo not only by HGF itself but also by VEGF and FGF2 [157]. 
Today glycomics can benefit from a wider exploitation of bioinformatics (functional to the  
“in silico” screening of AGFs/GAGs interactions based on molecular dynamics simulation of the 
docking events between the binding partners [44,48,88]) flanked to technologies such as surface 
plasmon resonance [135], mass spectrometry (MS), matrix-assisted laser desorption/ionization MS, 
NMR and Raman spectroscopy, aimed to identify the conformational features required to GAGs and 
AGFs to bind each other [309,310].  
The process of heparin-like drug discovery would involve large libraries of heparin-like compounds, 
making mandatory the use of oligosaccharide synthesizers [311] and carbohydrate microarrays [312]. 
The feasibility of this approach is sustained by “pilot” studies performed using library of heparin-derived 
octasaccharides [276], sulfated linked cyclitols [313], suramin-like polysulfonated distamycine 
derivatives [121,314], HS-mimetic glycoconjugates [282] and combinatorial library screening for 
heparin/HS GAGs [315]. Remarkable is the use of chemical libraries based on four component 
condensation reactions of isocyanides that, screened for the simultaneous inhibition of VEGF and FGF2, 
yield candidates drugs with interesting relationships of structure and activity [316]. 
Several antiangiogenic heparin-like compounds display multitarget activity: in mice, systemic 
administration of pentosan polysulfate inhibits the growth of tumors generated by the injection of VEGF, 
FGF2, pleiotrophin and midkine producing cells [30]. Pentosan polysulfate also binds and inhibits  
Tat [183] and FGF2 in vitro [317]. Accordingly, in phase I and II clinical trials it leads to stabilization 
of Kaposi’s sarcoma [318], a lesion in which Tat and FGF2 act synergistically [28]. Also, LHT7 could 
block VEGF-A, FGF2 and PDGF-B simultaneously [251]. Further interesting developments in this 
direction are represented by the production of an orally active low molecular weight heparin conjugate 
(LHTD4) that inhibit both VEGF-A and FGF2 [250]. 
A tight link exist among angiogenesis, virus infection, tumor and inflammation that relies on  
viral proteins, cytokines, receptors and adhesion molecules that “cross-contribute” to the different 
processes [289,290]. Interestingly, many of the heparin-binding AGFs (i.e., FGFs, HGF, PDGF, CXCL8, 
Tat and p17) act as pleiotropic cytokines, targeting cell types other than endothelium (i.e., promoting 
mural cell deposition, stimulating of tumor cell proliferation, maintaining an inflammatory status known 
to promote tumor progression or enhancing oncogenic virus replication/spreading). These proteins can 
be thus envisaged as “molecular overlaps” among the different pathological processes, representing 
promising targets for the development of multitarget drugs acting not only on angiogenesis but also on 
tumor growth and/or related inflammation and virus-infection. 
Effectively, a simultaneous inhibition of both angiogenesis and tumor growth can be achieved by 
compounds that mask HSPGs to AGFs: recombinant PF-4 inhibits at once angiogenesis [319], tumor 
growth [235] and metastasization [320]. This same multitarget approach is at the bases of the development 
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of an compounds generated by the fusion of a modified heparin (LHT7) with cyclic RGDyk. The 
resulting cRGD-LHT7 binds to both αvβ3 integrin expressed on the surface of tumor and endothelial 
cells and to VEGF, resulting in a strong antiangiogenic, anti-tumor activity [321]. 
Among the various antiangiogenic compounds, K5 derivatives emerge as particularly interesting 
“biotechnological heparin”. They are polysaccharides derived by Escherichia coli whose controlled 
sulfation confers the capability to bind (and inhibit) different AGF simultaneously, including  
FGF2 [267,322], VEGF [260] and the non-canonical AGFs gremlin [60], Tat [277] and p17 [72]. Also, 
they are able to prevent the binding of a given AGF to different pro-angiogenic receptors (i.e., Tat to 
HSPGs and integrin αvβ3 [277], FGF2 to HSPGs, FGFR1 and integrin αvβ3 [267,322] (Figure 6). 
Finally, beside angiogenesis [42], K5 derivatives have been demonstrated to be active also in preventing 
virus infection [323], tumor growth [324], thromboembolism [325] and inflammation [326] (Figure 6).  
 
Figure 6. Multitarget activity of K5 derivatives. K5 derivatives interfere with different, 
tightly intertwined processes such as inflammation, thromboembolism, virus infection, tumor 
growth and angiogenesis (upper panel). Regarding angiogenesis, K5 derivatives have been 
demonstrated to act by binding and sequestering different AGFs (lower left panel) and to 
inhibit the binding of a given AGF to different pro-angiogenic receptors simultaneously 
(lower right panel). 
Thus, K5 derivatives are representative of a “new generation” heparin-like compounds acting as 
global inhibitors that can disable multiple signaling networks, targeting nodal points at the crossroads 
of distinct molecular networks and thus expected to cause an overall failure of the disease-related system. 
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